The effects of Rituximab and Cyclosporine

Comparison of the effects of rituximab and cyclosporine on the treatment of patients aged 1 to 18 years with steroid-resistant nephrotic syndrome

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240614062128N1

Enrollment

Registered

2024-08-17

Start date

2024-08-22

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Steroid-resistant nephrotic syndrome.

Interventions

Intervention 1: Intervention group 1: Treatment with Rituximab. Intervention 2: Intervention group 2: treatment with Cyclosporine.

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Resistant to Nephrotic Syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The effectiveness of the drug on the amount of edema. Timepoint: Finally, one year for each patient. Method of measurement: Clinical symptoms based on the degree of edema.;The effectiveness of the drug on the amount of albumin. Timepoint: Finally, one year for each patient. Method of measurement: Albumin - laboratory.;The effectiveness of the drug on blood cells. Timepoint: Finally, one year for each patient. Method of measurement: Counting blood cells - laboratory.;The effectiveness of the drug on the ratio of protein to creatinine. Timepoint: Finally, one year for each patient. Method of measurement: Measuring the ratio of Protein to Creatinine - laboratory.	—

Measure

Time frame

The effectiveness of the drug on the amount of edema. Timepoint: Finally, one year for each patient. Method of measurement: Clinical symptoms based on the degree of edema.;The effectiveness of the drug on the amount of albumin. Timepoint: Finally, one year for each patient. Method of measurement: Albumin - laboratory.;The effectiveness of the drug on blood cells. Timepoint: Finally, one year for each patient. Method of measurement: Counting blood cells - laboratory.;The effectiveness of the drug on the ratio of protein to creatinine. Timepoint: Finally, one year for each patient. Method of measurement: Measuring the ratio of Protein to Creatinine - laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Fallah Tafti

Ghoum University of Medical Sciences

f.fallahtafti@gmail.com+98 25 3107 1100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026